Table 3.

APOE genotype (ε4+ or ε4−), dementia status, and clinical diagnosis of dementia; proportion of subjects with moderate or frequent neuritic plaques according to CERAD neuropathologic scoring; and proportion of subjects with neuropathologic AD according to modified consensus criteria (i.e., subjects with moderate or frequent plaques and Stages IV, V, or VI neurofibrillary pathology)

APOE genotypeDementia status and clinical diagnosisModerate or frequent neuritic plaques, n (%)Neuropathologic AD, n (%)
*† Regardless of APOE genotype, neuropathologic AD was significantly (p = 0.007) more common in the clinical AD group than in the no-dementia group.
‡ In subjects without APOE ε4, neuropathologic AD was significantly (p = 0.023) more common in the clinical AD group than in the clinical VaD or other group.
§ In the no-dementia group, neuropathologic AD was nonsignificantly (p = 0.107) associated with APOE ε4 allele.
∥ In the clinical AD group, neuropathologic AD was significantly (p = 0.001) more common in APOE ε4 carriers than in noncarriers.
¶ In the clinical VaD or other group, neuropathologic AD was significantly (p < 0.001) more common in APOE ε4 carriers than in noncarriers.
CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; VaD = vascular dementia.
ε4−No dementia24 /50 (48)8 /50 (16)*,§
Dementia
AD17 /27 (63)12 /27 (44)*,‡,∥
VaD or other19 /38 (50)7 /38 (18)‡,¶
ε4+No dementia10 /12 (83)5 /12 (42)†,§
Dementia
AD22 /24 (92)21 /24 (88)†,
VaD or other27 /29 (93)21/29 (72)